Timothy J Daskivich1, Kang-Hsien Fan2, Tatsuki Koyama2, Peter C Albertsen3, Michael Goodman4, Ann S Hamilton5, Richard M Hoffman6, Janet L Stanford7, Antoinette M Stroup8, Mark S Litwin9, David F Penson10. 1. Department of Urology, David Geffen School of Medicine, University of California, Los Angeles, CA. Electronic address: Tdaskivich@ucla.edu. 2. Department of Biostatistics, Vanderbilt University, Nashville, TN. 3. Division of Urology, Department of Surgery, School of Medicine, University of Connecticut, Farmington, CT. 4. Department of Epidemiology, Emory University, Atlanta, GA. 5. Department of Preventative Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA. 6. Department of Internal Medicine, University of New Mexico, Albuquerque, NM. 7. Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA. 8. Department of Internal Medicine, University of Utah, Salt Lake City, UT. 9. Department of Urology, David Geffen School of Medicine, University of California, Los Angeles, CA; Department of Health Policy and Management, Fielding School of Public Health, University of California, Los Angeles, CA. 10. Department of Urologic Surgery, Vanderbilt University, Nashville, TN; VA Tennessee Valley Geriatric Research, Education, and Clinical Centers, Nashville, TN.
Abstract
OBJECTIVE: To provide population-based estimates of other-cause mortality by age and comorbidity in men with prostate cancer for use at the point of care in shared decision making. MATERIALS AND METHODS: We sampled 3183 men with nonmetastatic prostate cancer from the Prostate Cancer Outcomes Study, a US population-based prospective cohort. Survival analysis accounting for competing risks was used to provide predictions of other-cause and cancer-specific mortality by age, comorbidity, and tumor risk through 14 years of follow-up. RESULTS: Older men had a higher absolute risk of other-cause mortality associated with comorbidity. For men with comorbidity counts of 0, 1, 2, and 3+, cumulative incidence of other-cause mortality at 14 years was 9%, 18%, 30%, and 35% for those younger than 60 years; 26%, 26%, and 48%, and 52% for those aged 60-70 years; and 49%, 57%, 66%, and 74% for those older than 70 years. Prostate cancer mortality at 14 years was 5%, 8%, and 23% for men with low-, intermediate-, and high-risk disease. Competing risk pictograms for each age/comorbidity/tumor-risk pair provide visual characterization of these risks over time. CONCLUSION: Our survival tables may be used at the point of care as part of shared decision making. Men aged >60 years with multiple comorbidities have substantial risk of other-cause mortality within 15 years of diagnosis and should consider conservative management for low-risk disease, given its low incidence of cancer-specific mortality. Men with high-risk disease, regardless of age or comorbidity, are at greater risk for cancer mortality and may still be appropriate candidates for aggressive treatment.
OBJECTIVE: To provide population-based estimates of other-cause mortality by age and comorbidity in men with prostate cancer for use at the point of care in shared decision making. MATERIALS AND METHODS: We sampled 3183 men with nonmetastatic prostate cancer from the Prostate Cancer Outcomes Study, a US population-based prospective cohort. Survival analysis accounting for competing risks was used to provide predictions of other-cause and cancer-specific mortality by age, comorbidity, and tumor risk through 14 years of follow-up. RESULTS: Older men had a higher absolute risk of other-cause mortality associated with comorbidity. For men with comorbidity counts of 0, 1, 2, and 3+, cumulative incidence of other-cause mortality at 14 years was 9%, 18%, 30%, and 35% for those younger than 60 years; 26%, 26%, and 48%, and 52% for those aged 60-70 years; and 49%, 57%, 66%, and 74% for those older than 70 years. Prostate cancer mortality at 14 years was 5%, 8%, and 23% for men with low-, intermediate-, and high-risk disease. Competing risk pictograms for each age/comorbidity/tumor-risk pair provide visual characterization of these risks over time. CONCLUSION: Our survival tables may be used at the point of care as part of shared decision making. Men aged >60 years with multiple comorbidities have substantial risk of other-cause mortality within 15 years of diagnosis and should consider conservative management for low-risk disease, given its low incidence of cancer-specific mortality. Men with high-risk disease, regardless of age or comorbidity, are at greater risk for cancer mortality and may still be appropriate candidates for aggressive treatment.
Authors: Ian Thompson; James Brantley Thrasher; Gunnar Aus; Arthur L Burnett; Edith D Canby-Hagino; Michael S Cookson; Anthony V D'Amico; Roger R Dmochowski; David T Eton; Jeffrey D Forman; S Larry Goldenberg; Javier Hernandez; Celestia S Higano; Stephen R Kraus; Judd W Moul; Catherine M Tangen Journal: J Urol Date: 2007-06 Impact factor: 7.450
Authors: A L Potosky; L C Harlan; J L Stanford; F D Gilliland; A S Hamilton; P C Albertsen; J W Eley; J M Liff; D Deapen; R A Stephenson; J Legler; C E Ferrans; J A Talcott; M S Litwin Journal: J Natl Cancer Inst Date: 1999-10-20 Impact factor: 13.506
Authors: A V D'Amico; R Whittington; S B Malkowicz; D Schultz; K Blank; G A Broderick; J E Tomaszewski; A A Renshaw; I Kaplan; C J Beard; A Wein Journal: JAMA Date: 1998-09-16 Impact factor: 56.272
Authors: Joo Yong Lee; Ho Won Kang; Koon Ho Rha; Nam Hoon Cho; Young Deuk Choi; Sung Joon Hong; Kang Su Cho Journal: J Cancer Res Clin Oncol Date: 2015-12-12 Impact factor: 4.553
Authors: Andrew T Wong; Joseph J Safdieh; Justin Rineer; Joseph Weiner; David Schwartz; David Schreiber Journal: Int Urol Nephrol Date: 2015-09-02 Impact factor: 2.370
Authors: Sarathi Kalra; Spyridon Basourakos; Angela Abouassi; Mary Achim; Robert J Volk; Karen E Hoffman; John W Davis; Jeri Kim Journal: Nat Rev Urol Date: 2016-03-22 Impact factor: 14.432
Authors: Sahyun Pak; Dalsan You; In Gab Jeong; Dong-Eun Lee; Sung Han Kim; Jae Young Joung; Kang-Hyun Lee; Jun Hyuk Hong; Choung-Soo Kim; Hanjong Ahn Journal: Cancer Res Treat Date: 2020-07-03 Impact factor: 4.679
Authors: Daniel M Frendl; Gordon FitzGerald; Mara M Epstein; Jeroan J Allison; Mitchell H Sokoloff; John E Ware Journal: PLoS One Date: 2020-12-07 Impact factor: 3.240